Lab21 Secures New Patents in Hepatitis C Drug Resistance and Fluorescent Carbon-based Nanoparticle Technology
News Dec 08, 2010
The hepatitis C patent extends an existing patent, and refers to technology allowing the genotypic identification of drug resistant mutations in the 4 major global genotypes of HCV. With the imminent launch of a series of new small molecule therapies in HCV, this technology will allow accurate monitoring of when drug resistance appears in individual patients, improving patient care.
The SelahDOTS™ nanoparticles technology covers a generic approach to the development of new diagnostic and imaging reagents using carbon-based non-toxic nanoparticles. This platform technology has multiple applications in clinical diagnostics and was originally developed through a licence from Clemson University. The grant of the patent now allows Lab21 to develop a series of new product and service applications in areas such as in vivo imaging, immunodiagnostics and point-of-care biomarker analysis,
The securing of these patents builds on Lab21’s growing intellectual property portfolio as it expands its competitive proprietary position in pharmacogenetic markers, disease markers and its assay technology.
Dr Berwyn Clarke, CSO at Lab21 commented: ‘The HCV patent further strengthens our portfolio in the important HCV diagnostic area while the nanoparticle platform technology has potential to transform the ways in which particulate diagnostics are used, particularly in vivo, where particle-related toxicity has been a significant problem. Additionally we are seeing early development progress in incorporating the SelahDOTS™ technology in our own new molecular and protein based assays.’
Graham Mullis, Lab21 CEO added: ‘The development of an extensive intellectual property portfolio will be an important part of Lab21’s strategy as we continue to grow. Patents such as these will ensure we are able to remain uniquely competitive and ensure we are able to provide our customers with the most advanced products and services in the markets we choose to serve.’
Researchers conducted a census of the Japanese population around 2,500 years ago using the Y chromosomes of men living on the main islands of modern-day Japan. This is the first time analysis of modern genomes has estimated the size of an ancient human population before they were met by a separate ancient population.READ MORE
Thanks in part to the popular film Finding Nemo, clownfishes are well known to the public and well represented in scientific literature. But the same can't be said for the equally colorful sea anemones--venomous, tentacled animals--that protect clownfishes and that the fish nourish and protect in return. That is, until now.READ MORE